Innovent Biologics ( (HK:1801) ) has issued an announcement.
Innovent Biologics, Inc. has updated the terms of reference for its Nomination Committee, which was originally established in 2018. The committee’s purpose is to identify and recommend candidates for the board of directors, oversee board performance evaluations, and develop nomination guidelines in line with applicable laws and regulations. This update aims to ensure the committee’s operations align with the latest governance standards, potentially impacting the company’s strategic direction and governance practices.
More about Innovent Biologics
Innovent Biologics, Inc. is a company incorporated in the Cayman Islands, primarily focused on the biopharmaceutical industry. It specializes in the development and commercialization of biologic medicines, with a market focus on innovative therapies for the treatment of cancer and other major diseases.
YTD Price Performance: 27.73%
Average Trading Volume: 14,200
Technical Sentiment Signal: Sell
Current Market Cap: $9.73B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.